Isavuconazole Could Be Useful for Treating Cerebral Aspergillosis

In a European retrospective study, isavuconazole was equivalent to voriconazole as first-line therapy and slightly inferior as salvage treatment for CA.

Cerebral aspergillosis (CA) usually occurs in immunocompromised patients and has a poor prognosis. Although voriconazole is the drug of choice for managing CA, isavuconazole has fewer toxicities and drug-drug interactions that might make it preferable. To examine if isavuconazole has similar efficacy to voriconazole, investigators conducted a European multicenter retrospective audit of adults and children who had received isavuconazole for CA; they then compared the outcomes to those in a control group of 119 patients with CA in the Cerebral Aspergillus Lesional Study (CEREALS), a French national cohort obtained between 2006 and 2018.

Among 40 patients across Europe with proven or probable CA, 10 received isavuconazole as first-line therapy …

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Isavuconazole Could Be Useful for Treating Cerebral Aspergillosis

Topics

Reviewing Author